Co-founder & CEO, GV20Therapeutics | Genomics & AI-Enabled Cancer Biotherapeutics
Hope to see everyone at the 25th HYSTA annual conference. https://lnkd.in/evWse39n
关于我们
寻百会公司于2016年成立，在美国波士顿和中国上海设有分部。寻百会利用高通量功能基因组学和人工智能技术来寻找肿瘤免疫药物的新靶点，开发有效的抗体药物。截至目前，寻百会独有的抗体药物研发引擎已经产出了一系列用于肿瘤免疫治疗的候选抗体药物。欲了解详情请访问公司网站 https://gv20tx.com/。
- 网站
-
https://gv20tx.com
寻百会的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2016
- 领域
- AI、Antibody、Immunotherapy和Genomics
地点
寻百会员工
动态
-
GV20 Therapeutics to Speak at ACCESS CHINA Partnering Forum September 24th, 2024 (Shanghai) — We are glad to announce that Dr. Xiaole Shirley Liu, the Co-founder and Chief Executive Officer of GV20 Therapeutics, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. https://lnkd.in/gUQe2ehk
-
-
寻百会转发了
Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute will present clinical data on the GV20-0251 program during an oral presentation at the?European Society for Medical Oncology (ESMO)?Annual Meeting 2024 in Barcelona, Spain. https://lnkd.in/gExSEPa2
-
Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute will present clinical data on the GV20-0251 program during an oral presentation at the?European Society for Medical Oncology (ESMO)?Annual Meeting 2024 in Barcelona, Spain. https://lnkd.in/gExSEPa2
-
Each year, The Posse Foundation identifies honorees who exhibit leadership, make significant contributions in the field of education, and positively affect people’s lives. We are thrilled to share that our Principal Scientist, Flavian D. Brown, was selected for the Posse Alumni category. He was recognized for his leadership, compassion, and ability to work in a team. He applies these qualities to his scientific world by mentoring younger scientists and leading teams worldwide. Take a minute and watch this beautiful spotlight on who Flavian is and all the great work he’s doing for science. #oncology #biotech #AI #PosseHonoree
-
GV20 Therapeutics’ Chief Business Officer, Ying Gong, PhD, will be attending #BIO2024.?If you are in San Diego, meet with us to discuss our pipeline including GV20-0251, a first-in-class antibody targeting a novel innate immune checkpoint IGSF8, and our AI-based novel target and antibody discovery platform. Check out our latest partnering news: https://lnkd.in/g_wn8qpc #partnering #oncology #biotech #AI #ML
-
GV20 Therapeutics’ Co-founder and Chief Executive Officer, Xiaole Shirley Liu, PhD, will be at #ASCO24.?We look forward to sharing clinical progress on GV20-0251 with industry colleagues and researchers.?This program targets IGSF8, a novel immune checkpoint that inhibits the function of natural killer cells and dendritic cells. By releasing this inhibition, GV20-0251 has the potential to become another pillar in cancer immunotherapy and bring significant benefits to cancer patients. Check out our recent peer-reviewed publication in Cell on this exciting program!?https://lnkd.in/gti_aXuZ We invite you to connect with us! #oncology #biotech #AI #ASCO24 #ML
-
Today, we announced our participation in the upcoming Jefferies Healthcare Conference Private Biotech Day. More details here: https://bit.ly/3QU9MnH
-
Exciting news! We were awarded first place at the 2024 Biomedical Pitch Competition, organized by HKSTP - Hong Kong Science and Technology Parks Corporation and?Boston Chinese Investment Club (BCIC), competing against 14 top biomedical teams. Using advanced genomics and AI, GV20 Therapeutics identifies new cancer immunology drug targets and develops effective antibody drugs, building a strong portfolio of immuno-oncology candidates for cancer treatment. ? #oncology #biotech